Ụlọ IPHASE DS8201a

IPHASE DS8201a

Nkọwa dị mkpirikpi:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

Kpọtụrụ ugbu a Tinye n'ụgbọ ịzụ ahịa

Nkọwa ngwaahịa

Mkpado ngwaahịa

Nkọwa ngwaahịa DS-8201a, nke a makwaara dị ka trastuzumab deruxtecan (T-DXd), bụ mgbochi mgbochi ọgwụ conjugate (ADC) emebere maka ọgwụgwọ nke HER2- ọrịa cancer ndị dị mma. Ọ na-ejikọta HER2-mgbochi monoclonal na-eche nche (dị ka trastuzumab) yana onye na-eme ihe ike topoisomerase I (deruxtecan) dị ka ụgwọ ọrụ cytotoxic. Ọgwụ ahụ na-ebunye chemotherapy ozugbo na mkpụrụ ndụ kansa na-ekwupụta HER2, na-eme ka ọ dị mma ma na-amachi mmebi nke sel nkịtị.

Otu:
Cathepsin
Ihe NO:
015200.01
Nha nkeji:
50uL,2mg/mL
Anụ ahụ:
N/A
Ụdị:
N/A
Ọnọdụ nchekwa na njem njem:
Na-echekwa na -70°C. Akpụrụ akpụ akpụ.